Prestige Brands (PBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Guidance

Go back to Prestige Brands (PBH) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Guidance

Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

February 5, 2026 6:00 AM EST

Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS

TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.

We exceeded our third... More